Indication and selection of pediatric patients for genetically modified T cells
for the SBTMO Technical manual of cellular therapy
DOI:
https://doi.org/10.46765/2675-374X.2022v3n2p173Keywords:
chimeric antigen receptor, acute lymphoblastic leukemia, pediatric, hematopoietic stem cell transplantationAbstract
The use of CAR-T cells will completely change the treatment of many hematological diseases, including relapsed pediatric B-lineage acute lymphoblastic leukemia. This article is part of the Brazilian Society of Bone Marrow Transplantation (SBTMO)’s “Technical manual of cellular therapy” to guide physicians to select patients and indicate the use of the CAR-T cells in pediatric patients with acute lymphoblastic leukemia. Other aspects of CAR-T cell therapy and management of important toxicities are included on other articles of this volume.
Downloads
Published
11/23/2022
How to Cite
Seber, A. (2022). Indication and selection of pediatric patients for genetically modified T cells : for the SBTMO Technical manual of cellular therapy. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(2), 173. https://doi.org/10.46765/2675-374X.2022v3n2p173
Issue
Section
Original article
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
